Search

Your search keyword '"Gaillard, S."' showing total 1,253 results
Start Over Author "Gaillard, S."
1,253 results on '"Gaillard, S."'

2. Anestesia-rianimazione nella chirurgia dell’ipofisi

Author

Hijazi, D., Jacquens, A., Tabillon, C., Doirado, M., Belkebir, K., Monsel, S., Mathon, B., Baussart, B., Gaillard, S., and Degos, V.

Abstract

La chirurgia dell’ipofisi per via trans-sfenoidale è il trattamento degli adenomi ipofisari intrasellari. Questa via d’accesso rispetta le vie ottiche e consente l’adenomectomia selettiva con conservazione di una funzione anteipofisaria normale. La tecnica chirurgica per via endoscopica si è diffusa negli ultimi anni. Le manifestazioni cliniche degli adenomi ipofisari dipendono dalla presenza o meno di una sindrome tumorale e dall’ipersecrezione ormonale. La sostituzione ormonale perioperatoria si è semplificata e le sue modalità differiscono a seconda dello stato endocrino. L’intervento è di breve durata e si esegue in posizione semiseduta. La difficoltà di gestione delle vie aeree domina il periodo intraoperatorio nel paziente acromegalico. Le complicanze sono rare e sono principalmente di ordine metabolico (diabete insipido).

Published
2024
Full Text
View/download PDF

3. Transport of laser accelerated proton beams and isochoric heating of matter

Author

Roth, M., Alber, I., Bagnoud, V., Brown, C., Clarke, R., Daido, H., Fernandez, J., Flippo, K., Gaillard, S., Gauthier, C., Glenzer, S., Gregori, G., Günther, M., Harres, K., Heathcote, R., Kritcher, A., Kugland, N., LePape, S., Li, B., Makita, M., Mithen, J., Niemann, C., Nürnberg, F., Offermann, D., Otten, A., Pelka, A., Riley, D., Schaumann, G., Schollmeier, M., Schütrumpf, J., Tampo, M., Tauschwitz, A., Tauschwitz, A. N., Roth, M., Alber, I., Bagnoud, V., Brown, C., Clarke, R., Daido, H., Fernandez, J., Flippo, K., Gaillard, S., Gauthier, C., Glenzer, S., Gregori, G., Günther, M., Harres, K., Heathcote, R., Kritcher, A., Kugland, N., LePape, S., Li, B., Makita, M., Mithen, J., Niemann, C., Nürnberg, F., Offermann, D., Otten, A., Pelka, A., Riley, D., Schaumann, G., Schollmeier, M., Schütrumpf, J., Tampo, M., Tauschwitz, A., and Tauschwitz, A. N.

Abstract

The acceleration of intense proton and ion beams by ultra-intense lasers has matured to a point where applications in basic research and technology are being developed. Crucial for harvesting the unmatched beam parameters driven by the relativistic electron sheath is the precise control of the beam. We report on recent experiments using the PHELIX laser at GSI, the VULCAN laser at RAL and the TRIDENT laser at LANL to control and use laser accelerated proton beams for applications in high energy density research. We demonstrate efficient collimation of the proton beam using high field pulsed solenoid magnets, a prerequisite to capture and transport the beam for applications. Furthermore we report on two campaigns to use intense, short proton bunches to isochorically heat solid targets up to the warm dense matter state. The temporal profile of the proton beam allows for rapid heating of the target, much faster than the hydrodynamic response time thereby creating a strongly coupled plasma at solid density. The target parameters are then probed by X-ray Thomson scattering (XRTS) to reveal the density and temperature of the heated volume. This combination of two powerful techniques developed during the past few years allows for the generation and investigation of macroscopic samples of matter in states present in giant planets or the interior of the earth.

Published
2024

6. Determination of the optimal dose of ephedrine in the treatment of arterial hypotension due to general anesthesia in neonates and infants below 6 months old: the ephedrine study protocol for a randomized, open-label, controlled, dose escalation trial

Author

Szostek, A. S., Boucher, P., Subtil, F., Zerzaihi, O., Saunier, C., de Queiroz Siqueira, M., Merquiol, F., Martin, P., Granier, M., Gerst, A., Lambert, A., Storme, T., Chassard, D., Nony, P., Kassai, B., and Gaillard, S.

Published
2021
Full Text
View/download PDF

11. A high-quality genome sequence of Rosa chinensis to elucidate ornamental traits

Author

Hibrand Saint-Oyant, L., Ruttink, T., Hamama, L., Kirov, I., Lakhwani, D., Zhou, N. N., Bourke, P. M., Daccord, N., Leus, L., Schulz, D., Van de Geest, H., Hesselink, T., Van Laere, K., Debray, K., Balzergue, S., Thouroude, T., Chastellier, A., Jeauffre, J., Voisine, L., Gaillard, S., Borm, T. J. A., Arens, P., Voorrips, R. E., Maliepaard, C., Neu, E., Linde, M., Le Paslier, M. C., Bérard, A., Bounon, R., Clotault, J., Choisne, N., Quesneville, H., Kawamura, K., Aubourg, S., Sakr, S., Smulders, M. J. M., Schijlen, E., Bucher, E., Debener, T., De Riek, J., and Foucher, F.

Published
2018
Full Text
View/download PDF

14. Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient-CEntric ClinicAl TRial PLatforms.

Author

Dhaenens, B.A.E., Mahler, F.M., Batchelor, H., Dicks, P., Gaillard, S., Nafria, B., Kopp-Schneider, A., Ribeiro, M.A., Schwab, M., Sparber-Sauer, M., Leubner, J., Wildt, S.N. de, Oostenbrink, R., Dhaenens, B.A.E., Mahler, F.M., Batchelor, H., Dicks, P., Gaillard, S., Nafria, B., Kopp-Schneider, A., Ribeiro, M.A., Schwab, M., Sparber-Sauer, M., Leubner, J., Wildt, S.N. de, and Oostenbrink, R.

Abstract

01 augustus 2023, Contains fulltext : 295947.pdf (Publisher’s version ) (Open Access), Advice from multiple stakeholders is required to design the optimal pediatric clinical trial. We present recommendations for acquiring advice from trial experts and patients/caregivers, derived from advice meetings that were performed through a collaboration of the Collaborative Network for European Clinical Trials for Children (c4c) and the European Patient-CEntric ClinicAl TRial PLatforms (EU-PEARL). Three advice meetings were performed: (1) an advice meeting for clinical and methodology experts, (2) an advice meeting for patients/caregivers, and (3) a combined meeting with both experts and patients/caregivers. Trial experts were recruited from c4c database. Patients/caregivers were recruited through a patient organization. Participants were asked to provide input on a trial protocol, including endpoints, outcomes, and the assessment schedule. Ten experts, 10 patients, and 13 caregivers participated. The advice meetings resulted in modification of eligibility criteria and outcome measures. We have provided recommendations for the most effective meeting type per protocol topic. Topics with limited options for patient input were most efficiently discussed in expert advice meetings. Other topics benefit from patient/caregiver input, either through a combined meeting with experts or a patients/caregivers-only advice meeting. Some topics, such as endpoints and outcome measures, are suitable for all meeting types. Combined sessions profit from synergy between experts and patients/caregivers, balancing input on protocol scientific feasibility and acceptability. Both experts and patients/caregivers provided critical input on the presented protocol. The combined meeting was the most effective methodology for most protocol topics. The presented methodology can be used effectively to acquire expert and patient feedback.

Published
2023

15. Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study

Author

Zamanipoor Najafabadi, Amir H, primary, van der Meulen, Merel, additional, Priego Zurita, Ana Luisa, additional, Faisal Ahmed, S, additional, van Furth, Wouter R, additional, Charmandari, Evangelia, additional, Hiort, Olaf, additional, Pereira, Alberto M, additional, Dattani, Mehul, additional, Vitali, Diana, additional, de Graaf, Johan P, additional, Biermasz, Nienke R, additional, _, _, additional, Steenvoorden, D, additional, Bowring, I, additional, van der Klauw, MM, additional, Vergeer, RA, additional, Losa, M, additional, Mortini, P, additional, Drake, W, additional, Grieve, J, additional, Didi, M, additional, Mallucci, C, additional, Shaikh, MG, additional, Hassan, S, additional, Jorgensen, JOL, additional, Albarazi, M, additional, Zaharieva, S, additional, Hadzhiyanev, A., additional, Tóth, M, additional, Sípos, L, additional, Unuane, D, additional, D'Haens, J, additional, Feldt-Rasmussen, U, additional, Poulsgaard, L, additional, Brue, T, additional, Dufour, H, additional, Bertherat, J, additional, Gaillard, S, additional, Karavitaki, N, additional, Ahmed, S, additional, Unger, N, additional, Kreitschmann-Andermahr, I, additional, Gaztambide, S, additional, Pomposo, I, additional, Gan, H-W, additional, Dorward, N, additional, Fliers, E, additional, Hoogmoed, J, additional, Scaroni, C, additional, Denaro, L, additional, Nordenström, A, additional, Olsson, M, additional, Zilaitiene, B, additional, Tamašauskas, A, additional, Persani, L, additional, Lasio, G, additional, Maiter, D, additional, Raftopoulos, C, additional, Volke, V, additional, Rätsep, T, additional, Matarazzo, P, additional, Peretta, P, additional, Deutschbein, T, additional, Perez, J, additional, Zucchini, S, additional, Mazzatenta, D, additional, Grottoli, S, additional, Zenga, F, additional, Devuyst, F, additional, De Witte, O, additional, Gatto, F, additional, Rossi, D, additional, Schilbach, K, additional, Rachinger, W, additional, Beckers, A, additional, Martin, D, additional, Al-Mrayat, M, additional, Mathad, N, additional, Neggers, SJCMM, additional, Dallenga, AHG, additional, Lebl, J, additional, Tichy, M, additional, Reincke, MM, additional, van de Ven, AC, additional, van Lindert, E, additional, Kotnik, P, additional, Bošnjak, R, additional, Biagetti, B, additional, Cordero, E, additional, Colao, A, additional, and Cappabianca, P, additional

Published
2023
Full Text
View/download PDF

20. 158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA

Author

Moroney, J., primary, Yeku, O., additional, Fleming, G., additional, Emens, L.A., additional, Vaena, D., additional, Dumbrava, E.E., additional, Rasco, D., additional, Sharma, M.R., additional, Papadopoulos, K., additional, Patnaik, A., additional, Sullivan, R.J., additional, Adewoye, H.H., additional, Ophir, E., additional, Cojocaru, G., additional, Ferre, P.J., additional, Izar, B., additional, and Gaillard, S., additional

Published
2022
Full Text
View/download PDF

22. Lysine demethylase KDM1A et expression ectopique du récepteur du GIP dans les adénomes hypophysaires somatotropes

Author

Chasseloup, F., primary, Tosca, L., additional, Proust, A., additional, Kuhn, E., additional, Hage, M., additional, Jublanc, C., additional, Occhi, G., additional, Regazzo, D., additional, Salenave, S., additional, Gaillard, S., additional, Parker, F., additional, Boch, A.L., additional, Bouligand, J., additional, Chanson, P., additional, and Kamenicky, P., additional

Published
2022
Full Text
View/download PDF

23. Efficacité et facteurs prédictifs de la réponse à l’immunothérapie dans les carcinomes hypophysaires et les tumeurs hypophysaires agressives : une étude française de cohorte

Author

Ilie, M., primary, Villa, C., additional, Cuny, T., additional, Assie, G., additional, Baussart, B., additional, Cancel, M., additional, Chanson, P., additional, Cortet, C., additional, Decoudier, B., additional, Deluche, E., additional, Stefano, A.L. Di, additional, Drui, D., additional, Gaillard, S., additional, Goichot, B., additional, Huillard, O., additional, Joncour, A., additional, Ciron, D. Larrieu, additional, Libe, R., additional, Guillaume, N., additional, Vasiljevic, A., additional, and Raverot, G., additional

Published
2022
Full Text
View/download PDF

24. Signatures transcriptomiques d’agressivité des tumeurs neuroendocrines hypophysaires (PitNETs)

Author

Benanteur, N., primary, Villa, C., additional, De Murat, D., additional, Boëzennec, R., additional, Armignacco, R., additional, Jouinot, A., additional, Letourneur, F., additional, Perlemoine, K., additional, Allassonniere, S., additional, Raffin-Sanson, M.L., additional, Emile, J.F., additional, Gaillard, S., additional, Bertherat, J., additional, Baussart, B., additional, and Assie, Pr G., additional

Published
2022
Full Text
View/download PDF

29. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Author

Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D, Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., Lorusso D., Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D, Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., and Lorusso D.

Abstract

Objective: The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer. Methods: Patients were randomly assigned (1:1) to lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk (experimental arm), versus PLD 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1–5 q3wk (control arm). Stratification factors were PS (0 vs. ≥1), prior PFI (1–3 months vs. >3 months), and prior chemotherapy lines (1–2 vs. 3). The primary endpoint was PFS by Independent Review Committee in all randomized patients. This study was registered with ClinicalTrials.gov, NCT02421588. Results: 442 patients were randomized: 221 in lurbinectedin arm and 221 in control arm (127 PLD and 94 topotecan). With a median follow-up of 25.6 months, median PFS was 3.5 months (95% CI, 2.1–3.7) in the lurbinectedin arm and 3.6 months (95% CI, 2.7–3.8) in the control arm (stratified log-rank p = 0.6294; HR = 1.057). Grade ≥ 3 treatment-related adverse events (AEs) were most frequent in the control arm: 64.8% vs. 47.9% (p = 0.0005), mainly due to hematological toxicities. The most common grade ≥ 3 AEs were: fatigue (7.3% of patients) and nausea (5.9%) with lurbinectedin; mucosal inflammation (8.5%) and fatigue (8.0%) in the control arm. Conclusions: The primary endpoint of improvement in PFS was not met. Lurbinectedin showed similar antitumor efficacy and was better tolerated than current standard of care in patients with platinum-resistant ovarian cancer.

Published
2021

31. Ten simple rules for failing successfully in academia.

Author

Gaillard, S, van Viegen, T, Veldsman, M, Stefan, MI, Cheplygina, V, Gaillard, S, van Viegen, T, Veldsman, M, Stefan, MI, and Cheplygina, V

Abstract

Failure is an integral part of life and by extension academia. At the same time, failure is often ignored, with potentially negative consequences both for the science and the scientists involved. This article provides several strategies for learning from and dealing with failure instead of ignoring it. Hopefully, our recommendations are widely applicable, while still taking into account individual differences between academics. These simple rules allow academics to further develop their own strategies for failing successfully in academia.

Published
2022

32. Neuropsychological and neuroanatomical phenotype in 17 patients with cystinosis

Author

Curie, A., Touil, N., Gaillard, S., Galanaud, D., Leboucq, N., Deschênes, G., Morin, D., Abad, F., Luauté, J., Bodenan, E., Roche, L., Acquaviva, C., Vianey-Saban, C., Cochat, P., Cotton, F., Bertholet-Thomas, A., Laboratoire sur le langage, le cerveau et la cognition (L2C2), École normale supérieure - Lyon (ENS Lyon)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut de Recherche en Horticulture et Semences (IRHS), Université d'Angers (UA)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Neuroradiologie [Hôpital Gui de Chauliac], Hôpital Gui de Chauliac [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Robert Debré Paris, Hôpital Robert Debré, Structural Impact Laboratory (SIMLab), Centre for Research-based Innovation (CRI), Norwegian University of Science and Technology [Trondheim] (NTNU), Norwegian University of Science and Technology (NTNU)-Norwegian University of Science and Technology (NTNU), Hôpital Henry Gabrielle [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Maladies Héréditaires du Métabolisme, Centre de Biologie et pathologie Est, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de néphrologie, rhumatologie et dermatologie pédiatriques [Hôpital Femme Mère Enfant, HCL], Hospices Civils de Lyon (HCL)-Hôpital Mère Enfant, RMN et optique : De la mesure au biomarqueur, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospital Clinical Research Program, École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université d'Angers (UA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-INSTITUT AGRO Agrocampus Ouest, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Intelligence Tests, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Adolescent, Research, [SDV]Life Sciences [q-bio], Intelligence, Cystinosis, lcsh:R, Neuropsychological profile, lcsh:Medicine, Neuroimaging, Neuropsychological Tests, Phenotype, [SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Child, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background Cystinosis is a rare autosomal recessive disorder caused by intracellular cystine accumulation. Proximal tubulopathy (Fanconi syndrome) is one of the first signs, leading to end-stage renal disease between the age of 12 and 16. Other symptoms occur later and encompass endocrinopathies, distal myopathy and deterioration of the central nervous system. Treatment with cysteamine if started early can delay the progression of the disease. Little is known about the neurological impairment which occurs later. The goal of the present study was to find a possible neuroanatomical dysmorphic pattern that could help to explain the cognitive profile of cystinosis patients. We also performed a detailed review of the literature on neurocognitive complications associated with cystinosis. Methods 17 patients (mean age = 17.6 years, [5.4–33.3]) with cystinosis were included in the study. Neuropsychological assessment was performed including intelligence (Intelligence Quotient (IQ) with Wechsler’s scale), memory (Children Memory Scale and Wechsler Memory Scale), visuo-spatial (Rey’s figure test) and visuo-perceptual skills assessments. Structural brain MRI (3 T) was also performed in 16 out of 17 patients, with high resolution 3D T1-weighted, 3D FLAIR and spectroscopy sequences. Results Intellectual efficiency was normal in patients with cystinosis (mean Total IQ = 93). However the Perceptual Reasoning Index (mean = 87, [63–109]) was significantly lower than the Verbal Comprehension Index (mean = 100, [59–138], p = 0.003). Memory assessment showed no difference between visual and verbal memory. But the working memory was significantly impaired in comparison with the general memory skills (p = 0.003). Visuospatial skills assessment revealed copy and reproduction scores below the 50th percentile rank in more than 70% of the patients. Brain MRI showed cortical and sub-cortical cerebral atrophy, especially in the parieto-occipital region and FLAIR hypersignals in parietal, occipital and brain stem/cerebellum. Patients with atrophic brain had lower Total IQ scores compared to non-atrophic cystinosis patients. Conclusions Patients with cystinosis have a specific neuropsychological and neuroanatomical profile. We suggest performing a systematic neuropsychological assessment in such children aiming at considering adequate management.

Published
2020
Full Text
View/download PDF

38. Additional file 4 of Successful intergeneric transfer of a major apple scab resistance gene (Rvi6) from apple to pear and precise comparison of the downstream molecular mechanisms of this resistance in both species

Author

Perchepied, L., Chevreau, E., Ravon, E., Gaillard, S., Pelletier, S., Bahut, M., Berthelot, P., Cournol, R., Schouten, H. J., and Vergne, E.

Abstract

Additional File 4: Fig. S1. Functional analyze of eight pear transgenic lines. Primers are given in Table S5. A) Schematic representation of the T-DNA of the plasmid pMF1, LB & RB: left and right borders, P35S: promoter of the 35S gene of the Cauliflower Mosaic Virus, TNOS: terminator of the nopaline synthase gene of agrobacterium, CODA-NPTII: respectively negative-positive selection genes, REC-LBD: recombinase gene post translationally inducible with a ligand thanks to a ligand biding domain (LBD), RS: recombinase recognition sites, confer [96] for more details about this marker-free plant production system. P1.6MDRBCS: 1600 base pairs (bp) length promoter of the small subunit of the HM222639 Malus domestica rbc gene, TMDRBCS: terminator of the small subunit of the HM222639 Malus domestica rbc gene, RVI6: coding sequence of the AJ297740 Malus domestica Rvi6 gene. Location on the T-DNA of a) primers allowing the pMdRbc1.6-Rvi6 633 bp fragment amplification, c) primers allowing the nptII 176 bp fragment amplification, e) primers allowing the Rvi6 131 bp fragment amplification used in QPCR transgene expression determination. B) transgene copy number estimated by QPCR. C) Validation of transgenicity of eight lines by PCR amplifications. Labelling of the molecular ladder is given in kilobase. Primers a) and c) are already detailed in A). b) primers allowing the agrobacterium tumefaciens 23S ribosomal RNA 184 bp fragment amplification, d) primers allowing the elongation factor EF1�� 400 bp fragment amplification. C, S, AK, AM, AO, AS, AT, AU: identification code of the transgenic lines in the series ���60���, CF: wild type variety ���Conference���, N: water as negative control of PCR, P: DNA of agrobacterium strain containing the plasmid PMF1 as a positive control for in planta T-DNA elements and agrobacterium presence. Fig. S2: Functional categories of DEGs at T0 in apple (GalaRvi6 / Gala, on the left) and pear (60 AU / Conference, on the right). The number of up- or down-regulated DEGs is expressed as a percentage of the total number of genes present in the Pyrus v1.0 (43,906 genes) and AriANE v2.0 (66,792 genes) microarrays, respectively. DEGs are classified in functional categories according to MapMan 3.5.1R2 bins. Only bins with ���6 DEGs are presented

Published
2021
Full Text
View/download PDF

39. Additional file 1 of Successful intergeneric transfer of a major apple scab resistance gene (Rvi6) from apple to pear and precise comparison of the downstream molecular mechanisms of this resistance in both species

Author

Perchepied, L., Chevreau, E., Ravon, E., Gaillard, S., Pelletier, S., Bahut, M., Berthelot, P., Cournol, R., Schouten, H. J., and Vergne, E.

Abstract

Additional File 1: Table S1. Scab qualitative note of nine transgenic pear lines and non-transgenic Conference inoculated with three V. pyrina strains. Percentage of plants in the different classes of symptoms, 42 days after inoculation. Table S4. Expression modulation of cell wall related DEGs detected at 8, 24 or 72 h post-inoculation during apple (GalaRvi6 / Gala) and pear (60 AU / Conference) responses to V. inaequalis and V. pyrina, respectively. In red: up-regulated DEGs, in blue: down-regulated DEGs

Published
2021
Full Text
View/download PDF

48. Successful intergeneric transfer of a major apple scab resistance gene (Rvi6) from apple to pear and precise comparison of the downstream molecular mechanisms of this resistance in both species

Author

Perchepied, L., primary, Chevreau, E., additional, Ravon, E., additional, Gaillard, S., additional, Pelletier, S., additional, Bahut, M., additional, Berthelot, P., additional, Cournol, R., additional, Schouten, H.J., additional, and Vergne, E., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results